217 related articles for article (PubMed ID: 37818799)
1. Immune-epithelial cell cross-talk enhances antiviral responsiveness to SARS-CoV-2 in children.
Magalhães VG; Lukassen S; Drechsler M; Loske J; Burkart SS; Wüst S; Jacobsen EM; Röhmel J; Mall MA; Debatin KM; Eils R; Autenrieth S; Janda A; Lehmann I; Binder M
EMBO Rep; 2023 Dec; 24(12):e57912. PubMed ID: 37818799
[TBL] [Abstract][Full Text] [Related]
2. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children.
Loske J; Röhmel J; Lukassen S; Stricker S; Magalhães VG; Liebig J; Chua RL; Thürmann L; Messingschlager M; Seegebarth A; Timmermann B; Klages S; Ralser M; Sawitzki B; Sander LE; Corman VM; Conrad C; Laudi S; Binder M; Trump S; Eils R; Mall MA; Lehmann I
Nat Biotechnol; 2022 Mar; 40(3):319-324. PubMed ID: 34408314
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Variant Delta Potently Suppresses Innate Immune Response and Evades Interferon-Activated Antiviral Responses in Human Colon Epithelial Cells.
Tandel D; Sah V; Singh NK; Potharaju PS; Gupta D; Shrivastava S; Sowpati DT; Harshan KH
Microbiol Spectr; 2022 Oct; 10(5):e0160422. PubMed ID: 36073824
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
5. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-I/MDA5, TRIF, and STING signaling pathways.
Deng J; Zheng Y; Zheng SN; Nan ML; Han L; Zhang J; Jin Y; Pan JA; Gao C; Wang PH
J Med Virol; 2023 Mar; 95(3):e28561. PubMed ID: 36755358
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 and its beta variant of concern infect human conjunctival epithelial cells and induce differential antiviral innate immune response.
Singh S; Garcia G; Shah R; Kramerov AA; Wright RE; Spektor TM; Ljubimov AV; Arumugaswami V; Kumar A
Ocul Surf; 2022 Jan; 23():184-194. PubMed ID: 34583089
[TBL] [Abstract][Full Text] [Related]
9. Interferon antagonists encoded by SARS-CoV-2 at a glance.
Lee JH; Koepke L; Kirchhoff F; Sparrer KMJ
Med Microbiol Immunol; 2023 Apr; 212(2):125-131. PubMed ID: 35366686
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous Detection of RIG-1, MDA5, and IFIT-1 Expression Is a Convenient Tool for Evaluation of the Interferon-Mediated Response.
Lozhkov AA; Plotnikova MA; Egorova MA; Baranovskaya IL; Elpaeva EA; Klotchenko SA; Vasin AV
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298646
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation.
Thorne LG; Reuschl AK; Zuliani-Alvarez L; Whelan MVX; Turner J; Noursadeghi M; Jolly C; Towers GJ
EMBO J; 2021 Aug; 40(15):e107826. PubMed ID: 34101213
[TBL] [Abstract][Full Text] [Related]
13. Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients.
Hou Y; Zhou Y; Jehi L; Luo Y; Gack MU; Chan TA; Yu H; Eng C; Pieper AA; Cheng F
Aging Cell; 2022 Feb; 21(2):e13544. PubMed ID: 35023286
[TBL] [Abstract][Full Text] [Related]
14. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
[TBL] [Abstract][Full Text] [Related]
15. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease.
Samuel CE
J Biol Chem; 2023 Aug; 299(8):104960. PubMed ID: 37364688
[TBL] [Abstract][Full Text] [Related]
16. Free ISG15 and Protein ISGylation Emerging in SARS-CoV-2 Infection.
Tecalco Cruz AC
Curr Drug Targets; 2022; 23(7):686-691. PubMed ID: 35297347
[TBL] [Abstract][Full Text] [Related]
17. ACE2 expression is related to the interferon response in airway epithelial cells but is that functional for SARS-CoV-2 entry?
Scagnolari C; Bitossi C; Viscido A; Frasca F; Oliveto G; Scordio M; Petrarca L; Mancino E; Nenna R; Riva E; De Vito C; Midulla F; Antonelli G; Pierangeli A
Cytokine; 2021 Apr; 140():155430. PubMed ID: 33508651
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons.
Rother N; Yanginlar C; Lindeboom RGH; Bekkering S; van Leent MMT; Buijsers B; Jonkman I; de Graaf M; Baltissen M; Lamers LA; Riksen NP; Fayad ZA; Mulder WJM; Hilbrands LB; Joosten LAB; Netea MG; Vermeulen M; van der Vlag J; Duivenvoorden R
Cell Rep Med; 2020 Dec; 1(9):100146. PubMed ID: 33377122
[TBL] [Abstract][Full Text] [Related]
19. Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.
Shuai H; Chu H; Hou Y; Yang D; Wang Y; Hu B; Huang X; Zhang X; Chai Y; Cai JP; Chan JF; Yuen KY
J Infect; 2020 Oct; 81(4):e1-e10. PubMed ID: 32707230
[TBL] [Abstract][Full Text] [Related]
20. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.
Zhao X; Chen D; Li X; Griffith L; Chang J; An P; Guo JT
J Mol Biol; 2022 Mar; 434(6):167438. PubMed ID: 34990653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
